March 15, 2024
Chugai Pharmaceutical said on March 14 that it has filed a new drug application for its anti-CD20xCD3 bispecific antibody mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior systemic...read more